Wednesday, July 9, 2014





Pfizer: Once-a-day Lyrica failed in epilepsy trial


February 19. 2013 5:40PM
Story Tools
PrintPrint | E-MailEMail | SaveSave | Hear Generate QR Code QR
Send to Kindle


(AP) Pfizer says that a long-lasting version of its anti-seizure drug Lyrica failed to significantly decrease epilepsy symptoms when compared with placebo.


The company said Friday that a study of two doses of once-a-day pregabalin CR showed the pills were well tolerated, but did not meet the study's goal of decreasing seizure frequency. The company tracked patients' seizures for 28 days while taking the drug and compared that rate to an 8-week baseline period.


Pfizer said it will continue with two other studies evaluating the drug for fibromyalgia and post-herpetic neuralgia.


Lyrica is Pfizer's top-selling drug with sales of $1.04 billion in the most recent quarter. The regular formulation of the drug is approved to prevent seizures and pain associated with diabetes, shingles and fibromyalgia.


Pfizer Inc. shares rose a penny to $23.67 in midday trading.


Associated Press


Comments
comments powered by Disqus Commenting Guidelines
Poll
Mortgage Minute


Search for New & Used Cars

Make 
Model
 
Used New All
 

Search Times Leader Classifieds to find just the home you want!

Search Times Leader Classifieds to find just what you need!

Search Pet Classifieds
Dogs Cats Other Animals



Social Media/RSS
Times Leader on Twitter
Times Leader on Youtube
Times Leader on Google+
The Times Leader on Tumblr
The Times Leader on Pinterest
Times Leader RSS Feeds